Regulatory Clarity and Broad Rett Syndrome Opportunity Drive Taysha Gene Therapies Buy Rating and $10 Target

Needham analyst Gil Blum reiterated a Buy rating on Taysha Gene Therapies today and set a price target of $10.00.

Gil Blum has given his Buy rating due to a combination of factors tied to Taysha Gene Therapies’ regulatory progress and market opportunity for TSHA-102. The company obtained written confirmation from the FDA that limited additional safety data in young children, combined with successful results from the pivotal cohort in older patients, would be sufficient to seek approval for use in patients aged two and above. This agreement supports the potential for a broad label across a wide Rett syndrome population and clarifies the regulatory pathway.
Taysha has already initiated dosing in the pivotal cohort and laid out a clear timeline to complete both the REVEAL Part B and ASPIRE studies, with interim and topline data expected in the 2026–2027 timeframe that could support a comprehensive filing. The updated FDA feedback also removes uncertainty regarding differences in the addressable market between TSHA-102 and Neurogene’s competing program, as both are now positioned toward similarly broad age groups. Taken together, the regulatory clarity, expansive prospective label, defined clinical milestones, and competitive positioning underpin Blum’s decision to reiterate a Buy rating and maintain a $10 price target.

In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $11.00 price target.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TSHA in relation to earlier this year.